Department of Infectious Disease, Sheng Jing Hospital of China Medical University, Shenyang 110004, P.R. China.
Int J Mol Med. 2012 Dec;30(6):1438-42. doi: 10.3892/ijmm.2012.1155. Epub 2012 Oct 15.
The aim of this study was to investigate the association of mutations in the E2/NS1 [hypervariable regions 1 and 2 (HVR1 and HVR2)] and NS5A regions of the hepatitis C virus (HCV) genome and the effectiveness of interferon (IFN) therapy, and assess whether the degree of heterogeneity of HCV quasispecies predicts response to IFN treatment. Fourteen patients infected with HCV genotype 1b (HCV-1b) who were treated with pegylated IFN-α-2a and ribavirin for 24 weeks, were studied. E2/NS1 and NS5A gene segments were amplified by reverse-transcription polymerase chain reaction. HCV quasispecies heterogeneity in the E2/NS1 region was determined by cloning and sequencing. Mutations in the NS5A region were detected by direct sequencing. The heterogeneity of HCV quasispecies in the HVR1 was significantly greater in the non-responder group than in the responder group, but was not significant for HVR2 or NS5A. The correlation between mutations in IFN sensitivity-determining region (ISDR, NS5A2209-2248) and IFN sensitivity could not be supported. The degree of quasispecies heterogeneity in HVR1, but not in HVR2 and NS5A, may be predictive of response to IFN therapy. An ISDR may not apply to patients infected with HCV-1b.
本研究旨在探讨丙型肝炎病毒(HCV)基因组 E2/NS1 [高变区 1 和 2(HVR1 和 HVR2)]和 NS5A 区突变与干扰素(IFN)治疗效果的相关性,并评估 HCV 准种异质性的程度是否可预测 IFN 治疗的反应。我们对 14 例接受聚乙二醇干扰素-α-2a 和利巴韦林治疗 24 周的 HCV-1b 感染患者进行了研究。采用逆转录聚合酶链反应扩增 E2/NS1 和 NS5A 基因片段。通过克隆和测序确定 E2/NS1 区 HCV 准种异质性。通过直接测序检测 NS5A 区的突变。非应答组的 HVR1 区 HCV 准种异质性明显大于应答组,但 HVR2 区和 NS5A 区无明显差异。ISDR(NS5A2209-2248)中的 IFN 敏感性决定区突变与 IFN 敏感性之间的相关性无法得到支持。HVR1 区准种异质性的程度可能与 IFN 治疗的反应相关,但 HVR2 区和 NS5A 区无明显差异。ISDR 可能不适用于感染 HCV-1b 的患者。